OUTBACK: Phase III Trial of CRT ± Adjuvant CT in Women With Locally Advanced Cervical Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
In women with locally advanced cervical cancer, use of adjuvant carboplatin/paclitaxel after standard cisplatin-based CRT did not improve OS or PFS at 5 years.
Format: Microsoft PowerPoint (.ppt)
File Size: 478 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings